All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - 2nd line (L2), ipilimumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CA184-024, 2011 0.72 [0.59; 0.87]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
MDX010 Ipi vs gp100, 2010 0.66 [0.51; 0.86]
0.75 [0.66 ; 0.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 55% 3,693 low not evaluable deaths (OS) (extension)detailed results CA184-024, 2011 0.69 [0.57; 0.84]
KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.60 ; 0.78 ] CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,112 moderate not evaluable PFS (extension)detailed results KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.53 ; 0.70 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
CA184-024, 2011 0.76 [0.63; 0.92]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.68 [0.56 ; 0.82 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 64% 2,341 moderate not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
CA184-024, 2011 1.15 [0.79; 1.68]
1.17 [0.92 ; 1.50 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011 2 0% 1,229 low not evaluable DORdetailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.68 [0.55 ; 0.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 25 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
CA184-024, 2011 1.56 [0.91; 2.65]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
MDX010 Ipi plus gp100 vs gp100, 2010 4.06 [0.94; 17.43]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
MDX010 Ipi vs gp100, 2010 8.24 [1.85; 36.76]
2.14 [1.18 ; 3.90 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 85% 3,693 low not evaluable AE (any grade)detailed results CA184-024, 2011 5.17 [1.48; 18.09]
MDX010 Ipi plus gp100 vs gp100, 2010 1.95 [0.54; 7.01]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
MDX010 Ipi vs gp100, 2010 0.99 [0.24; 4.05]
2.20 [1.14 ; 4.25 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 3% 1,784 low not evaluable AE (grade 3-4)detailed results CA184-024, 2011 3.39 [2.34; 4.94]
MDX010 Ipi plus gp100 vs gp100, 2010 0.94 [0.63; 1.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
MDX010 Ipi vs gp100, 2010 0.95 [0.59; 1.55]
1.33 [0.69 ; 2.56 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 90% 1,784 low not evaluable AE leading to death (grade 5)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.65 [0.46 ; 0.92 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CA184-024, 2011 5.64 [3.80; 8.35]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
MDX010 Ipi plus gp100 vs gp100, 2010 2.17 [1.28; 3.67]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
MDX010 Ipi vs gp100, 2010 1.09 [0.60; 1.98]
2.01 [1.31 ; 3.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 85% 3,577 low not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CA184-024, 2011 11.25 [6.30; 20.10]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
MDX010 Ipi plus gp100 vs gp100, 2010 1.64 [0.90; 2.99]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
MDX010 Ipi vs gp100, 2010 1.41 [0.69; 2.88]
1.77 [0.92 ; 3.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 91% 3,577 low not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 1.36 [0.28; 6.47]
1.58 [0.55 ; 4.50 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010 4 0% 2,332 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.28 [0.72 ; 2.27 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 74% 1,793 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.23 [1.51 ; 3.30 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.43 [0.27 ; 7.58 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 2,012 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.16 [0.16 ; 8.29 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
CA184-024, 2011 10.35 [0.56; 190.49]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
MDX010 Ipi plus gp100 vs gp100, 2010 8.58 [0.50; 146.20]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
MDX010 Ipi vs gp100, 2010 14.85 [0.83; 264.38]
1.16 [0.41 ; 3.33 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 77% 3,577 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CA184-024, 2011 21.14 [1.23; 363.94]
KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
MDX010 Ipi plus gp100 vs gp100, 2010 5.01 [0.65; 38.48]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
MDX010 Ipi vs gp100, 2010 6.29 [0.75; 52.98]
1.51 [0.74 ; 3.08 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 54% 3,577 low not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
MDX010 Ipi plus gp100 vs gp100, 2010 2.80 [0.15; 53.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
MDX010 Ipi vs gp100, 2010 10.44 [0.56; 193.00]
1.55 [0.34 ; 6.97 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 68% 2,012 low not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.64 [0.17 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
MDX010 Ipi plus gp100 vs gp100, 2010 8.05 [1.07; 60.32]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
MDX010 Ipi vs gp100, 2010 10.83 [1.37; 85.84]
2.16 [0.84 ; 5.60 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 69% 2,012 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
2.45 [0.95 ; 6.28 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 0% 3,577 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
MDX010 Ipi vs gp100, 2010 0.16 [0.01; 3.32]
0.53 [0.15 ; 1.80 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 3 0% 1,286 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
6.01 [0.30 ; 120.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.57 [0.07 ; 4.44 ] CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,565 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
1.00 [0.47 ; 2.10 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 0% 3,079 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CA184-024, 2011 1.02 [0.02; 51.42]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.09 [0.28 ; 4.24 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 0% 3,577 low not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CA184-024, 2011 52.70 [7.19; 385.99]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 0.17 [0.02; 1.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.47 [0.24 ; 8.98 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 70% 3,577 low not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CA184-024, 2011 32.40 [7.79; 134.72]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
2.34 [0.53 ; 10.34 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 63% 3,577 low serious Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.94 [0.15 ; 5.80 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.63 [0.29 ; 9.28 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.72 [0.08 ; 6.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CA184-024, 2011 10.35 [0.56; 190.49]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.31 [0.41 ; 4.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 0% 3,577 low not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 3.51 [0.19; 64.62]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
MDX010 Ipi vs gp100, 2010 2.02 [0.07; 60.83]
2.30 [0.86 ; 6.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 0% 3,577 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
MDX010 Ipi plus gp100 vs gp100, 2010 6.38 [0.37; 110.82]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.56 [0.33; 7.34]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
1.79 [0.77 ; 4.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 2,012 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CA184-024, 2011 1.02 [0.02; 51.42]
1.49 [0.11 ; 19.48 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011 2 0% 1,224 low not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.72 [0.08 ; 6.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.35 [0.01; 17.55]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.01; 17.42]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.49 [0.05 ; 4.76 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 3 0% 1,286 low not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.37 [0.11 ; 17.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results CA184-024, 2011 0.43 [0.11; 1.68]
MDX010 Ipi plus gp100 vs gp100, 2010 0.29 [0.09; 0.87]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
MDX010 Ipi vs gp100, 2010 0.28 [0.06; 1.36]
0.40 [0.20 ; 0.79 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.33 [0.14; 0.78]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.95 [0.30; 3.03]
MDX010 Ipi vs gp100, 2010 0.35 [0.11; 1.12]
0.44 [0.23 ; 0.84 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 3 12% 1,286 low not evaluable Asthenia AE (grade 3-4)detailed results CA184-024, 2011 0.17 [0.02; 1.39]
0.17 [0.02 ; 1.39 ] CA184-024, 2011 1 0% 498 NA not evaluable Chills AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Constipation AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
MDX010 Ipi plus gp100 vs gp100, 2010 1.04 [0.11; 10.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.07; 1.70]
MDX010 Ipi vs gp100, 2010 3.07 [0.32; 29.91]
0.80 [0.27 ; 2.38 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Cough AE (grade 3-4)detailed results CA184-024, 2011 2.04 [0.07; 60.99]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.99 [0.17 ; 5.76 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Decreased appetite AE (grade 3-4)detailed results CA184-024, 2011 0.76 [0.17; 3.43]
MDX010 Ipi plus gp100 vs gp100, 2010 0.51 [0.14; 1.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
MDX010 Ipi vs gp100, 2010 0.50 [0.09; 2.76]
0.65 [0.31 ; 1.39 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Diarrhoea AE (grade 3-4)detailed results CA184-024, 2011 21.14 [1.23; 363.94]
MDX010 Ipi plus gp100 vs gp100, 2010 6.13 [0.81; 46.56]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.83 [0.34; 2.05]
MDX010 Ipi vs gp100, 2010 7.40 [0.90; 60.98]
3.93 [0.81 ; 19.19 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 66% 1,784 low not evaluable Dyspnoea AE (grade 3-4)detailed results CA184-024, 2011 16.77 [0.96; 293.61]
MDX010 Ipi plus gp100 vs gp100, 2010 0.80 [0.30; 2.14]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.96 [0.34; 2.73]
MDX010 Ipi vs gp100, 2010 0.83 [0.25; 2.80]
1.03 [0.50 ; 2.13 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 25% 1,784 low not evaluable Fatigue AE (grade 3-4)detailed results CA184-024, 2011 2.44 [1.21; 4.94]
MDX010 Ipi plus gp100 vs gp100, 2010 1.68 [0.56; 5.04]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.71 [0.31; 1.62]
MDX010 Ipi vs gp100, 2010 2.36 [0.71; 7.87]
1.58 [0.84 ; 2.97 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 46% 1,784 low not evaluable Headache AE (grade 3-4)detailed results CA184-024, 2011 4.12 [0.46; 37.08]
MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.45 [0.10; 2.06]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
0.78 [0.33 ; 1.84 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 8% 1,784 low not evaluable Increase AST AE (grade 3-4)detailed results CA184-024, 2011 18.42 [5.64; 60.14]
18.42 [5.64 ; 60.14 ] CA184-024, 2011 1 0% 498 NA not evaluable Increased ALT AE (grade 3-4)detailed results Out of scale CA184-024, 2011 34.83 [8.39; 144.67]
34.83 [8.39 ; 144.67 ] CA184-024, 2011 1 0% 498 NA not evaluable Nausea AE (grade 3-4)detailed results CA184-024, 2011 1.36 [0.30; 6.14]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.17; 2.80]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.68 [0.17; 2.78]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
0.88 [0.42 ; 1.83 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Pruritus AE (grade 3-4)detailed results CA184-024, 2011 10.35 [0.56; 190.49]
10.35 [0.56 ; 190.49 ] CA184-024, 2011 1 0% 498 NA not evaluable Pyrexia AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
MDX010 Ipi plus gp100 vs gp100, 2010 0.34 [0.05; 2.47]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 0.25 [0.01; 5.58]
0.48 [0.12 ; 1.91 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Rash AE (grade 3-4)detailed results CA184-024, 2011 6.16 [0.31; 123.62]
6.16 [0.31 ; 123.62 ] CA184-024, 2011 1 0% 498 NA not evaluable Vomiting AE (grade 3-4)detailed results CA184-024, 2011 2.07 [0.61; 6.95]
MDX010 Ipi plus gp100 vs gp100, 2010 0.81 [0.21; 3.17]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.20; 3.14]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
1.13 [0.57 ; 2.24 ] CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 4 0% 1,784 low not evaluable Weight decreased AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.06; 16.34]
1.02 [0.06 ; 16.34 ] CA184-024, 2011 1 0% 498 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 13:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 286,69,129
- treatments: 850,329,558,579,549,868
